| EMA number | EMEA/H/C/004720 |
| ATC code | B02BX |
| Authorisation | 18 February 2019 |
| Withdrawn | 14 April 2026 |
| Revision | 9 |
Mulpleo is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures
MULPLETA — VANCOCIN ITALIA, approved 2018-07-31 (NDA210923).
31 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.